The new SA article probably should have had a different title, something along the lines of:
"KIDNEYS ARE OVER RATED''. Then he could go on to explain how fun it would be to attempt to live a full life with proteinuria, rotten kidneys, and constant hospitalizations, and of course, those pesky visits every other day to the dialysis treatment center.
GSK, even if they somehow stumble to market first, is holding a losing hand with Drisapersen. And that's not going to change, despite what the shorts wish. Hopefully the FDA stops #$%$ around sometime soon, and finally shows their cards. Until then, we'll have to endure idiots like the author of today's piece.